Beryl Drugs share news and announcements
BSE: 524606Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹24.89.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹13 Cr4,587th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 20.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 6.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 3.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.24
- Volume, BSEVolume. Shares traded on the last trading day.
- 31
Beryl Drugs share news and announcements
572 announcements, routine notices left out, newest first. Page 4 of 12.
Apr 2024
5 Apr · Compliance-57 (5) : intimation after the end of quarter
Feb 2024
12 Feb · Board meeting
1 Feb · Board meeting
Meeting on 12 Feb 2024: quarterly results
Jan 2024
6 Jan · Compliance-57 (5) : intimation after the end of quarter
Nov 2023
8 Nov · Board meeting
1 Nov · Board meeting
Meeting on 8 Nov 2023: quarterly results
Oct 2023
14 Oct · Compliance-57 (5) : intimation after the end of quarter
Sep 2023
21 Sep · Meeting
21 Sep · Meeting
Aug 2023
25 Aug · Board meeting
18 Aug · Board meeting
Meeting on 25 Aug 2023: annual general meeting12 Aug · Results
3 Aug · Board meeting
Meeting on 12 Aug 2023: quarterly results
Jul 2023
10 Jul · Compliance-57 (5) : intimation after the end of quarter
9 Jul · Compliance-57 (5) : intimation after the end of quarter
May 2023
30 May · Board meeting
29 May · Results
18 May · Board meeting
Meeting on 29 May 2023: audited results
Apr 2023
7 Apr · Compliance-57 (5) : intimation after the end of quarter
Mar 2023
Feb 2023
15 Feb · Results
13 Feb · Board meeting
3 Feb · Board meeting
Meeting on 13 Feb 2023: quarterly results
Nov 2022
14 Nov · Board meeting
4 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
Oct 2022
10 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0